JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kimmel, H. L.
Right arrow Articles by Kuhar, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kimmel, H. L.
Right arrow Articles by Kuhar, M. J.

Vol. 298, Issue 1, 129-140, July 2001

Dopamine D1 and D2 Receptors Influence Dopamine Transporter Synthesis and Degradation in the Rat

Heather L. Kimmel, Andrew R. Joyce, F. Ivy Carroll and Michael J. Kuhar

Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia (H.L.K., A.R.J., M.J.K.); and Research Triangle Institute, Research Triangle Park, North Carolina (F.I.C.)

Neurotransmitter transporters play an important role in maintaining synaptic homeostasis and in the actions of many drugs. Utilizing a technique for measuring the kinetics (synthesis, degradation, and half-life) of the dopamine transporter (DAT) protein in the rat striatum and nucleus accumbens, we have investigated the effects of systemic administration of dopamine receptor agonists and antagonists upon DAT kinetics in these brain regions. In the striatum, the dopamine D1 receptor agonist SKF38393 and the dopamine D1 receptor antagonist SCH23390 were without effect. However, the dopamine D2 receptor agonists R-(-)-propylnorapomorphine hydrochloride (NPA) and quinpirole decreased the half-life of DAT. This effect was blocked by the dopamine D2 antagonist eticlopride, which, by itself, increased the half-life of DAT. In the nucleus accumbens, the agonist SKF38393 increased the DAT half-life, whereas the antagonist SCH23390 decreased the half-life. In contrast to the striatum, NPA and quinpirole increased the DAT half-life, which was blocked by eticlopride and by itself had no effect on DAT kinetics. Cocaine increased the half-life of DAT in both the striatum and the nucleus accumbens. The results of the present study suggest that, through dopamine receptors, dopamine indirectly influences DAT protein turnover in the striatum and in the nucleus accumbens, but in different ways.

0022-3565/01/2981-0129$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Arch Gen PsychiatryHome page
D. P. Prata, A. Mechelli, M. M. Picchioni, C. H. Y. Fu, T. Toulopoulou, E. Bramon, M. Walshe, R. M. Murray, D. A. Collier, and P. McGuire
Altered Effect of Dopamine Transporter 3'UTR VNTR Genotype on Prefrontal and Striatal Function in Schizophrenia
Arch Gen Psychiatry, November 1, 2009; 66(11): 1162 - 1172.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
A. Bertolino, L. Fazio, A. Di Giorgio, G. Blasi, R. Romano, P. Taurisano, G. Caforio, L. Sinibaldi, G. Ursini, T. Popolizio, et al.
Genetically Determined Interaction between the Dopamine Transporter and the D2 Receptor on Prefronto-Striatal Activity and Volume in Humans
J. Neurosci., January 28, 2009; 29(4): 1224 - 1234.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
D. J. Brunswick, J. D. Amsterdam, P. D. Mozley, and A. Newberg
Greater Availability of Brain Dopamine Transporters in Major Depression Shown by [99mTc]TRODAT-1 SPECT Imaging
Am J Psychiatry, October 1, 2003; 160(10): 1836 - 1841.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. E. Ahlskog
Slowing Parkinson's disease progression: Recent dopamine agonist trials
Neurology, February 11, 2003; 60(3): 381 - 389.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. L. Kimmel, F. I. Carroll, and M. J. Kuhar
Withdrawal from Repeated Cocaine Alters Dopamine Transporter Protein Turnover in the Rat Striatum
J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 15 - 21.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
Y. Schmitz, C. Schmauss, and D. Sulzer
Altered Dopamine Release and Uptake Kinetics in Mice Lacking D2 Receptors
J. Neurosci., September 15, 2002; 22(18): 8002 - 8009.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. E. Ahlskog, D. M. Maraganore, R. J. Uitti, G. R. Uhl, R. L. Albin, T. E. Nichols, K. A. Frey, P. K. Morrish, K. Marek, J. Seibyl, et al.
Brain Imaging to Assess the Effects of Dopamine Agonists on Progression of Parkinson Disease
JAMA, July 17, 2002; 288(3): 311 - 313.
[Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.